Systemic Inflammatory Markers In Vocal Cord Lesions
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorAntalya Health Sciences University
About this trial
The aim of this study is to evaluate the levels of systemic inflammatory markers such as PIV, SII, and NPAR in patients with benign and premalignant laryngeal lesions and to determine the diagnostic accuracy of these values using ROC analysis.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Patients aged 18 years and older
Patients with a diagnosis of vocal cord lesion via endoscopic or surgical means
Patients with complete blood count and albumin data in their hospital records
Disqualifiers
Acute infection
Autoimmune disease
Other malignancy
Steroid use
Trial population
Inclusion was planned for patients aged 18 and over, with a diagnosis of vocal cord lesion via endoscopic or surgical means, and with complete blood count and albumin data in hospital records.
Trial design
Design model
Case-control
Time perspective
Retrospective
Treatments tested in this trial
Laryngeal polyps
Other interventionBening laryngeal lesions
Laryngeal nodules
Other interventionBening laryngeal lesions
Laryngeal cysts
Other interventionBening laryngeal lesions
Reinke's edema
Other interventionBening laryngeal lesions
Papillomas
Other interventionPremalign laryngeal lesions
Dysplasia
Other interventionPremalign laryngeal lesions
High-risk premalignant lesions
Other interventionPremalign laryngeal lesions
Malignant vocal cord lesions
Other interventionMalign laryngeal lesions
Asymptomatic smokers without vocal cord lesions
Other interventionNone laryngeal lesions
Treatment groups
250 Participants
are divided into 9 treatment groups9
Treatment groupsSee each treatment group below.
Group A: Laryngeal polyps1 intervention
Group B: Laryngeal nodules1 intervention
Group C: Laryngeal cysts1 intervention
Group D: Reinke's edema1 intervention
Group E: Papillomas1 intervention
Group F: Dysplasia1 intervention
Group G: High-risk premalignant lesions1 intervention
Group H: Malignant vocal cord lesions1 intervention
Group I: Control1 intervention
Trial outcomes
Primary outcomes
1
Determining the diagnostic accuracy of PIV
PIV (pan-immune-inflammation value)
Time frame
Postoperative 1 monthSecondary outcomes
1
Determining the diagnostic accuracy of NLR
NLR (neutrophil-lymphocyte ratio)
Time frame
Postoperative 1 month2
Determining the diagnostic accuracy of PLR
PLR (platelet-lymphocyte ratio)
Time frame
Postoperative 1 month3
Determining the diagnostic accuracy of HEO
HEO (hemoglobin-eosinophil ratio)
Time frame
Postoperative 1 month4
Determining the diagnostic accuracy of SII
SII (systemic immune-inflammation index)
Time frame
Postoperative 1 monthSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov
This trial is not recruiting at the moment. You can still explore other options: